Medtronic Payments for Repurchase of Common Stock decreased by 55.1% to $123.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 95.1%, from $2.49B to $123.00M. This is a positive signal — lower values indicate better performance for this metric.
Higher spending indicates a commitment to returning capital to shareholders or offsetting dilution from stock-based compensation.
The cash outflow associated with the company's repurchase of its own common shares from the open market. This is a prima...
Standard capital return metric for mature public companies.
other_payments_for_repurchase_of_common_stock| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $575.00M | $315.00M | $162.00M | $661.00M | $1.41B | $336.00M | $42.00M | $170.00M | $97.00M | $152.00M | $2.63B | $1.63B | $2.49B | $2.47B | $274.00M | $123.00M |
| QoQ Change | — | -45.2% | -48.6% | +308.0% | +112.7% | -76.1% | -87.5% | +304.8% | -42.9% | +56.7% | >999% | -38.1% | +53.1% | -1.0% | -88.9% | -55.1% |
| YoY Change | — | — | — | — | +144.5% | +6.7% | -74.1% | -74.3% | -93.1% | -54.8% | >999% | >999% | >999% | — | -83.2% | -95.1% |